Department of Preventive Medicine,
Department of Medicine
Basil Rigas has not added Biography.
If you are Basil Rigas and would like to personalize this page please email our Author Liaison for assistance.
Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress.
Proceedings of the National Academy of Sciences of the United States of America Nov, 2005 | Pubmed ID: 16282376
The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia.
Current opinion in gastroenterology Jan, 2007 | Pubmed ID: 17133086
Development of novel agents based on nitric oxide for the control of colon cancer.
Acta pharmacologica Sinica Sep, 2007 | Pubmed ID: 17723176
The novel phenylester anticancer compounds: Study of a derivative of aspirin (phoshoaspirin).
International journal of oncology Jan, 2008 | Pubmed ID: 18097547
NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action.
Nitric oxide : biology and chemistry Sep, 2008 | Pubmed ID: 18486630
A potentiometric protein sensor built with surface molecular imprinting method.
Biosensors & bioelectronics Sep, 2008 | Pubmed ID: 18514502
NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis?
PPAR research , 2008 | Pubmed ID: 18528523
NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts.
Carcinogenesis Sep, 2008 | Pubmed ID: 18544566
Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling.
Cancer letters Jan, 2009 | Pubmed ID: 18805632
Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats.
International journal of oncology Oct, 2008 | Pubmed ID: 18813794
The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.
Cancer research Oct, 2008 | Pubmed ID: 18922898
Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death.
Carcinogenesis Jan, 2009 | Pubmed ID: 18952595
Food components, alternative medicine, and cancer: progress and promise.
Nutrition and cancer , 2008 | Pubmed ID: 19003574
Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect.
Carcinogenesis Mar, 2009 | Pubmed ID: 19136474
Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.
Molecular carcinogenesis Oct, 2009 | Pubmed ID: 19415698
The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin.
International journal of oncology Oct, 2009 | Pubmed ID: 19724920
Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo.
Cancer research Mar, 2010 | Pubmed ID: 20215502
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
Gastroenterology Oct, 2010 | Pubmed ID: 20600034
Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
Carcinogenesis Nov, 2010 | Pubmed ID: 20627873
Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action.
Experimental cell research Jun, 2011 | Pubmed ID: 21406194
Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models.
The Journal of pharmacology and experimental therapeutics Jun, 2011 | Pubmed ID: 21422165
Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
Cancer prevention research (Philadelphia, Pa.) Jul, 2011 | Pubmed ID: 21464038
Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents.
The Journal of pharmacology and experimental therapeutics Sep, 2011 | Pubmed ID: 21646387
Structure-activity relationship study of novel anticancer aspirin-based compounds.
Molecular medicine reports Sep-Oct, 2011 | Pubmed ID: 21805049
Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.
Cancer research Dec, 2011 | Pubmed ID: 22025561
Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation.
Pharmaceutical research Jun, 2012 | Pubmed ID: 22072052
Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
The Journal of pharmacology and experimental therapeutics Feb, 2012 | Pubmed ID: 22085648
Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system.
Breast cancer research : BCR Jan, 2012 | Pubmed ID: 22293394
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents.
The Journal of pharmacology and experimental therapeutics Jun, 2012 | Pubmed ID: 22448039
Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.
British journal of pharmacology Sep, 2012 | Pubmed ID: 22489789
Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.
Stem cells (Dayton, Ohio) Oct, 2012 | Pubmed ID: 22653497
Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.
Pharmaceutical research Nov, 2012 | Pubmed ID: 22723123
In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22).
Pharmaceutical research Dec, 2012 | Pubmed ID: 22782648
Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.
International journal of oncology Oct, 2012 | Pubmed ID: 22842609
MC-12, an annexin A1-based peptide, is effective in the treatment of experimental colitis.
PloS one , 2012 | Pubmed ID: 22844504
Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives.
Nanomedicine (London, England) Oct, 2012 | Pubmed ID: 23148540
Platinum folate nanoparticles toxicity: cancer vs. normal cells.
Toxicology in vitro : an international journal published in association with BIBRA Mar, 2013 | Pubmed ID: 23318730
The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies.
Carcinogenesis Apr, 2013 | Pubmed ID: 23338686
Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.
Biochemical pharmacology Apr, 2013 | Pubmed ID: 23399640
Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.
Pharmaceutical research Jun, 2013 | Pubmed ID: 23483440
Aerosol administration of phospho-sulindac inhibits lung tumorigenesis.
Molecular cancer therapeutics Aug, 2013 | Pubmed ID: 23645590
Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice.
PloS one , 2013 | Pubmed ID: 23650499
Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.
International journal of oncology Sep, 2013 | Pubmed ID: 23807084
A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice.
Neoplasia (New York, N.Y.) Oct, 2013 | Pubmed ID: 24204197
Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate.
International journal of oncology Feb, 2014 | Pubmed ID: 24284479
Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress.
BMC cancer Feb, 2014 | Pubmed ID: 24575839
The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.
Biochemical pharmacology Sep, 2014 | Pubmed ID: 25044307
Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen.
The Journal of pharmacology and experimental therapeutics Oct, 2014 | Pubmed ID: 25047517
A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies.
International journal of pharmaceutics Dec, 2014 | Pubmed ID: 25311177
Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect.
PloS one , 2014 | Pubmed ID: 25369051
Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.
Pharmaceutical research May, 2015 | Pubmed ID: 25392229
Repurposing the antipsychotic trifluoperazine as an antimetastasis agent.
Molecular pharmacology , 2015 | Pubmed ID: 25552486
The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism.
The Journal of pharmacology and experimental therapeutics Apr, 2015 | Pubmed ID: 25589413
Altered Interactions between the Gut Microbiome and Colonic Mucosa Precede Polyposis in APCMin/+ Mice.
PloS one , 2015 | Pubmed ID: 26121046
NSAIDs and Colorectal Cancer Control: Promise and Challenges.
Current pharmacology reports Oct, 2015 | Pubmed ID: 26688785
The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.
Carcinogenesis Apr, 2016 | Pubmed ID: 26905586
Phospho-Aspirin (MDC-22) Prevents Pancreatic Carcinogenesis in Mice.
Cancer prevention research (Philadelphia, Pa.) Jul, 2016 | Pubmed ID: 27138793
Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles.
International journal of oncology Oct, 2017 | Pubmed ID: 28849098
Alkaline Ceramidase 1 Protects Mice from Premature Hair Loss by Maintaining the Homeostasis of Hair Follicle Stem Cells.
Stem cell reports 11, 2017 | Pubmed ID: 29056331
Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease.
Translational research : the journal of laboratory and clinical medicine 08, 2018 | Pubmed ID: 29702077
[Corrigendum] Phospho‑valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly‑(L)‑lactic acid‑poly(ethylene glycol) nanoparticles.
International journal of oncology 12, 2018 | Pubmed ID: 30320367
The Chemoprevention of Ovarian Cancer: the Need and the Options.
Current pharmacology reports , 2018 | Pubmed ID: 30363743
The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.
International journal of pharmaceutics Feb, 2019 | Pubmed ID: 30597269
A New Rabbit Model of Chronic Dry Eye Disease Induced by Complete Surgical Dacryoadenectomy.
Current eye research Aug, 2019 | Pubmed ID: 30983427
Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation.
Carcinogenesis Apr, 2019 | Pubmed ID: 30994173
Correction: The Chemoprevention of Ovarian Cancer: the Need and the Options.
Current pharmacology reports , 2018 | Pubmed ID: 31187022
NSAID-induced corneal melt: Clinical importance, pathogenesis, and risk mitigation.
Survey of ophthalmology Jan - Feb, 2020 | Pubmed ID: 31306671
Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
Carcinogenesis Oct, 2019 | Pubmed ID: 31584613
ACERCA DE JoVE
Copyright © 2024 MyJoVE Corporation. Todos los derechos reservados